Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Study of ORJ-001 for the Treatment of IPF

16 novembre 2026 mis à jour par: Oorja Bio, Inc.

A Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Tolerability (Part A), and Efficacy (Part B), of ORJ-001 in Patients With Idiopathic Pulmonary Fibrosis (ORBIT-IPF)

ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by patients and how long the drug stays in the body. Part B will test how well the drug affects lung function. Animal models of IPF have shown that ORJ-001 can repair damaged lung tissue and improve markers of lung function.

Aperçu de l'étude

Statut

Recrutement

Description détaillée

This Phase 2a/2b, randomized, double-blind, placebo-controlled, multicenter study will evaluate the safety, tolerability, and efficacy of ORJ-001 administered subcutaneously twice weekly in adults with IPF. The study consists of two parts. Part A will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of two dose levels of ORJ-001 compared with placebo over 12 weeks of treatment. Data from Part A will be reviewed by an independent Data Monitoring Committee to select the dose for Part B. Participants in Part A will not continue into Part B; Part B will enroll a separate cohort of participants. Part B will evaluate the efficacy of the selected ORJ-001 dose compared with placebo, with the primary efficacy endpoint being change from baseline in forced vital capacity (FVC) at Week 12. Secondary and exploratory assessments include percent predicted FVC, time to acute IPF exacerbation, respiratory hospitalization or death, patient-reported outcomes, pharmacokinetics, and biomarkers of fibrosis. Adults aged 40 years or older with confirmed IPF and adequate pulmonary function who are receiving stable antifibrotic standard-of-care therapy, or who have previously discontinued such therapy due to tolerability or lack of response, may be eligible to participate.

Type d'étude

Interventionnel

Inscription (Estimé)

95

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Alabama
      • Birmingham, Alabama, États-Unis, 35294
        • Recrutement
        • University of Alabama at Birmingham
        • Chercheur principal:
          • Tejaswini Kulkarni, MD
    • Florida
      • Doral, Florida, États-Unis, 33172
        • Recrutement
        • Innova Pharma Research, LLC
    • Pennsylvania
      • DuBois, Pennsylvania, États-Unis, 15801
        • Recrutement
        • Clinical Research Associates of Central PA

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

40 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Key Inclusion Criteria:

  1. Male or female participants aged ≥ 40 years when signing informed consent
  2. Non-smoker or ex-smoker who has stopped smoking for > 6 months prior to signing informed consent
  3. Diagnosis of IPF, as defined by 2022 international guidelines and confirmed by centrally adjudicated finding of a definite or probable UIP pattern on HRCT of the chest. The HRCT may be performed at screening or, if available, a historical HRCT obtained within 12 months from screening may be submitted for central review
  4. FVC of at least 45% of the predicted value and a DLCO, corrected for the hemoglobin level, of at least 25% and no greater than 90% of the predicted value. Note: Each test (FVC and DLCO) may be repeated once after a minimum of 24 hours if the initial result is deemed unreliable by the investigator
  5. If receiving SOC antifibrotic therapy, participants must be on a stable regimen of a single approved therapy for at least 60 days prior to the screening visit. Participants who have discontinued SOC antifibrotic therapy due to tolerability or lack of response may be enrolled after at least 30 days of discontinuing the SOC antifibrotic therapy.
  6. Negative serum pregnancy test in women of childbearing potential at the screening visit

Key Exclusion Criteria:

  1. Participants who are treatment-naïve with respect to SOC antifibrotic therapies
  2. Women who are pregnant, nursing, or who plan to become pregnant while in the trial
  3. Major surgery (including joint surgery) within 8 weeks from screening, or planned major surgery within 4 months following randomization
  4. Presence of one or more significant concurrent medical conditions that may affect the outcome of the study per investigator judgement
  5. Participants with relevant airway obstruction, defined as pre bronchodilator forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC) ratio < 0.7 at screening
  6. Lower respiratory tract infection requiring antibiotics within 4 weeks from screening, or during the screening period (may be rescreened following recovery)
  7. Acute IPF exacerbation within 3 months from screening, or during the screening period
  8. Receiving more than 15 mg per day of prednisone during screening

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Part A: ORJ-001 400 mg

Participants receive ORJ-001 400 mg administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. Randomization ratio: 3:1:1 (400 mg:200 mg:placebo).

ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated.

Matching placebo administered by subcutaneous injection twice weekly.

Expérimental: Part A: ORJ-001 200 mg

Participants receive ORJ-001 200 mg administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. Randomization ratio: 3:1:1 (active:active:placebo).

ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated.

Matching placebo administered by subcutaneous injection twice weekly.

Comparateur placebo: Part A: Placebo

Participants receive matching placebo administered subcutaneously (SC) twice weekly (BIW) for 12 weeks.

Matching placebo administered by subcutaneous injection twice weekly.

Expérimental: Part B: ORJ-001 (Selected Dose)

Participants receive the ORJ-001 dose selected based on Part A safety, tolerability, pharmacokinetic, pharmacodynamic, and efficacy data, administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. Participants are randomized 1:1 to ORJ-001 or placebo.

ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated.

Matching placebo administered by subcutaneous injection twice weekly.

Comparateur placebo: Part B: Placebo

Participants receive matching placebo administered subcutaneously (SC) twice weekly (BIW) for 12 weeks.

Matching placebo administered by subcutaneous injection twice weekly.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Part A: Safety and Tolerability of ORJ-001: Number of Participants with Treatment-Related Adverse Events (TEAEs)
Délai: From first dose through Safety Follow-up Visit, up to 12 weeks.

Number of participants experiencing at least one treatment-emergent adverse event.

From first dose through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Severity of Treatment-Emergent Adverse Events (TEAEs)
Délai: From first dose through Safety Follow-up Visit, up to 12 weeks.

Severity of treatment-emergent adverse events as graded according to CTCAE v6.0.

From first dose through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Systolic Blood Pressure
Délai: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.

Change from baseline in systolic blood pressure measured in millimeters of mercury (mmHg).

Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Body Temperature
Délai: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.

Change from baseline in body temperature measured in degrees Celsius (°C).

Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Heart Rate
Délai: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.

Change from baseline in heart rate measured in beats per minute (bpm).

Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Respiratory Rate
Délai: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.

Change from baseline in respiratory rate measured in breaths per minute.

Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Oxygen Saturation
Délai: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.

Change from baseline in oxygen saturation measured as percentage (% SpO₂).

Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Corrected QT Interval
Délai: Baseline, Week 4, Week 12, and Safety Follow-up Visit up to 12 weeks.

Change from baseline in corrected QT interval (QTc) measured by electrocardiogram (ECG) in milliseconds (ms).

Baseline, Week 4, Week 12, and Safety Follow-up Visit up to 12 weeks.
Part B: Change from Baseline in Forced Vital Capacity (FVC)
Délai: Baseline to Week 12

Change from baseline in FVC measured by spirometry at Week 12.

Baseline to Week 12

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Part B: Change From Baseline in Percent Predicted Forced Vital Capacity (FVC%)
Délai: Baseline to Week 12.

Change from baseline in percentage of predicted FVC measured by spirometry at Week 12.

Baseline to Week 12.
Part B: Time to Acute Exacerbation of IPF, Hospitalization for a Respiratory Cause, or Death
Délai: Up to Week 12.

Time, in days, to first occurrence of acute IPF exacerbation, hospitalization for a respiratory cause, or death.

Up to Week 12.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: Oorja Bio Medical Director, Oorja Bio, Inc.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 novembre 2026

Achèvement primaire (Estimé)

1 janvier 2029

Achèvement de l'étude (Estimé)

1 mars 2029

Dates d'inscription aux études

Première soumission

21 septembre 2026

Première soumission répondant aux critères de contrôle qualité

6 octobre 2026

Première publication (Réel)

9 octobre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner